NeoGenomics is pushing into newer blood-based cancer tests and broader genomic offerings, which could help it win more hospital and doctor business as demand for cancer testing keeps growing. But competition is intense and delays, legal disputes, and weaker spending from drug companies could slow progress and keep costs high.Read more
NeoGenomics benefits from the growing push toward more personalized cancer care, but a weak part of its business is leaving labs underused and hurting momentum. Big spending on new systems and new tests could improve efficiency over time, yet delays, legal issues, and tougher competition may keep growth and profits under pressure.Read more
NeoGenomics could ride an aging population and rising cancer testing needs, helped by newer test launches, digital tools, and lab automation that may improve speed and profitability. But competition is intensifying and the business leans on big customers and a shaky drug-company services segment, which could keep results bumpy.Read more
No trending discussion available.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
